AbCellera Biologics Inc. (ABCL)

NMS – Цена в реальном времени. Валюта: USD

4.95

-0.30 (-5.71%)

При закрытии: May 12, 2026, 4:00 PM EDT

07.05.2026

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in May and June 2026.

20.04.2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.

01.04.2026

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.

23.03.2026

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

06.03.2026

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

25.02.2026

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago.

25.02.2026

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

20.04.2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.

24.02.2026

AbCellera Reports Full Year 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.

12.01.2026

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause.

18.12.2025

AbCellera and Bruker Reach Global Settlement of Patent Litigation

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Bruker Reach Global Settlement of Patent Litigation.

AbCellera Biologics Inc. (ABCL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

AbCellera Biologics Inc. (ABCL)

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera Reports Full Year 2025 Business Results

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera Reports Full Year 2025 Business Results

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Search stocks

AbCellera Biologics Inc. (ABCL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

AbCellera Biologics Inc. (ABCL)

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera Reports Full Year 2025 Business Results

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera Reports Full Year 2025 Business Results

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation